BIOXCEL THERAPEUTICS INC (BTAI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.07-37.11%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BTAI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Obtain FDA approval for IGALMI to treat acute agitation in bipolar disorder and schizophrenia in the at-home setting by the PDUFA date.
Newly stated in 2026-Q1. The FDA accepted the sNDA for IGALMI for at-home use with a PDUFA date of November 14, 2026. Revenue from IGALMI was $206,000 in 2026-Q1, up from $168,000 in 2025-Q1, reflecting early commercial activity. The trajectory is consistent with management's focus on regulatory approval and launch preparation.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“FDA accepted sNDA for IGALMI use in at-home setting; PDUFA date Nov. 14, 2026.”
Progress clinical development of BXCL501 as a treatment for agitation associated with Alzheimer’s dementia.
Newly stated in 2026-Q1. Management highlighted advancing BXCL501 for agitation in Alzheimer’s dementia. No specific financial metrics or clinical milestones reported yet. The priority is in early stages with limited substantive delivery so far.
“Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer’s dementia.”
Engage advisors and explore potential transactions or collaborations to enhance shareholder value and advance IGALMI plans.
Newly stated in 2026-Q1. Management engaged MTS Health Partners to explore strategic options including sale, merger, collaboration, or financing to maximize shareholder value. No transaction completed yet; the priority is under active evaluation with limited substantive delivery so far.
“Evaluating strategic options with an advisor to maximize shareholder value and advance IGALMI plans.”
Develop and execute commercial launch plans for IGALMI in the at-home setting following regulatory approval.
Newly stated in 2026-Q1. Management has developed a comprehensive launch plan for IGALMI in the at-home setting. IGALMI net revenue increased from $168,000 in 2025-Q1 to $206,000 in 2026-Q1, reflecting early commercial activity. The trajectory shows initial progress in launch preparation.
“Preparing for commercial launch and developed comprehensive launch plan for IGALMI at-home setting.”
Manage financial position including cash, losses, and credit agreement compliance amid operational losses.
Newly stated in 2026-Q1. The company reported a net loss of $12.7 million in 2026-Q1, worsening from $7.3 million in 2025-Q1, with cash and equivalents at $17.2 million. Management states compliance with credit covenants amid financial challenges. The trajectory shows ongoing financial strain with active management focus.
“Company remains in compliance with the covenants in its Credit Agreement.”
Over the trailing year it converted 0.99x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
36 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.